[144] Sera Prognostics, Inc. SEC Filing
Rhea-AI Filing Summary
Sera Prognostics insider Paul Kearney filed a Form 144 to sell 6,460 Class A common shares of SERA, representing an aggregate market value of $16,410. The securities were acquired by restricted stock unit vesting on 08/08/2025 and the proposed sale is also dated 08/08/2025. The sale is to be executed through Morgan Stanley Smith Barney. The filing reports 38,061,868 shares outstanding for the issuer, giving context to the size of this sale.
The form also discloses two recent sales by the same person: 7,089 shares on 05/08/2025 (gross proceeds $17,315) and 1,311 shares on 06/10/2025 (gross proceeds $1,946). The notice includes the standard insider representation that no undisclosed material adverse information is known to the seller.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sale of 6,460 SERA shares is disclosed; size is immaterial relative to total shares outstanding.
The Form 144 shows Paul Kearney intends to sell 6,460 Class A shares with an aggregate value of $16,410, acquired via RSU vesting on the same date as the proposed sale. Compared with the issuer's 38,061,868 outstanding shares, this represents a negligible fraction of equity. Two prior small sales in May and June are also reported. From a financial-impact perspective, this filing is routine and unlikely to move valuation metrics or market perception materially.
TL;DR: Filing documents compliant insider sale activity; disclosure meets Rule 144 requirements and includes required seller representations.
The notice identifies the broker and shows the securities were acquired through restricted stock unit vesting, with sale execution via a registered broker-dealer, which aligns with standard compliance practice. The seller attests there is no undisclosed material adverse information. Given the small size of the transaction and prior recent disposals, this filing appears to be routine insider liquidity rather than a governance red flag.